Bactiguard Holding AB (publ)

BATS-CHIXE:BACTBS Stock Report

Market Cap: SEK 4.1b

Bactiguard Holding Past Earnings Performance

Past criteria checks 0/6

Bactiguard Holding's earnings have been declining at an average annual rate of -46%, while the Medical Equipment industry saw earnings declining at 9.5% annually. Revenues have been growing at an average rate of 7.2% per year.

Key information

-46.0%

Earnings growth rate

-44.8%

EPS growth rate

Medical Equipment Industry Growth-9.5%
Revenue growth rate7.2%
Return on equity-12.5%
Net Margin-30.2%
Next Earnings Update05 Apr 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Bactiguard Holding makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BATS-CHIXE:BACTBS Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 22212-641780
30 Jun 22196-661660
31 Mar 22187-651530
31 Dec 21175-591410
30 Sep 21216-441530
30 Jun 21203-501480
31 Mar 21170-381190
31 Dec 20177-381150
30 Sep 20155-26910
30 Jun 2018714880
31 Mar 2020691080
31 Dec 19190161040
30 Sep 1915591080
30 Jun 19128-151060
31 Mar 19149-101150
31 Dec 18150-151150
30 Sep 18160-101050
30 Jun 18159-101050
31 Mar 18143-15960
31 Dec 17151-3940
30 Sep 17142-10930
30 Jun 17142-10930
31 Mar 17140-12920
31 Dec 16124-27930
30 Sep 16116-39820
30 Jun 16139-32840
31 Mar 16133-34930
31 Dec 15135-27980

Quality Earnings: BACTBS is currently unprofitable.

Growing Profit Margin: BACTBS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BACTBS is unprofitable, and losses have increased over the past 5 years at a rate of 46% per year.

Accelerating Growth: Unable to compare BACTBS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BACTBS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-12.2%).


Return on Equity

High ROE: BACTBS has a negative Return on Equity (-12.54%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/11/29 04:30
End of Day Share Price 2022/09/01 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bactiguard Holding AB (publ) is covered by 1 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristofer Liljeberg-SvenssonCarnegie Commissioned Research